#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Impact of Lurasidone on Metabolic Functions Compared to Other Antipsychotics –⁠ Results of a Large Meta-Analysis

Antipsychotic therapy is associated with varying degrees of metabolic abnormalities in parameters of weight, lipid metabolism, and glucose metabolism. The presence of metabolic syndrome or isolated disorders of glucose and lipid metabolism further increases the risk of morbidity and mortality in patients with schizophrenia compared to the general population. Lurasidone is an antipsychotic indicated for the acute and maintenance treatment of schizophrenia. The advantage of this drug is its low risk of metabolic side effects, which has been confirmed in a recent large meta-analysis of clinical studies.
Source: Modern Treatment of Schizophrenia 24. 6. 2021

News Probiotics as a Means to Reduce the Incidence of Streptococcus Mutans

Data from a prospective study examining the effects of probiotics on the oral microbiome show the ability of orally administered probiotics to reduce the incidence of Streptococcus mutans and also positively affect the presence of lactobacilli in the oral cavity.
Source: GI, colic and microbiome 19. 4. 2022

News Subclinical Hypothyroidism in Pregnancy: How Great Are the Real Risks and Can They Be Effectively Reduced?

The aim of the meta-analysis by authors from the Mayo Clinic was to describe the impact of subclinical hypothyroidism on the course of pregnancy and the effect of levothyroxine replacement therapy in reducing the risk of possible complications.
Source: Thyroid Disorders 25. 4. 2023

News Current Treatment Options for Refractory/Relapsed CLL

How have treatment protocols for chronic lymphocytic leukemia changed in recent years? A review published in Acta Haematologica discusses the current therapeutic options for relapsed or refractory disease.
Source: Chronic Lymphocytic Leukemia 8. 9. 2022

News Memantine Eases Daily Life for Patients and Caregivers

What is the efficacy and safety of memantine in patients with Alzheimer's disease in routine practice in the Czech Republic? And to what extent can it ease the burden on caregivers of these patients?
Source: Cognitive in the treatment of Alzheimer's disease 12. 10. 2020

News Venotonics in Hemorrhoid Therapy –⁠ Results of a Systematic Review

Hemorrhoids are among the most common pathological findings in the anorectal area, and their incidence increases with age. Various modalities are used in the treatment of this condition, which has unpleasant health and psychological complications, aiming to alleviate the symptoms. Widely used and very popular are so-called venotonics, a large group of drugs and dietary supplements, mostly of natural origin, including diosmin.
Source: Venous Insufficiency 27. 3. 2020

News INFOGRAPHIC: LDL Cholesterol -⁠ Recommended Target Values

Elevated levels of LDL cholesterol are a significant risk factor for cardiovascular diseases, which remain the most common cause of death among adult Czechs. We have strong evidence about who and how LDL-c should be reduced, and ample treatment options to achieve this. Yet, more than half of the patients do not achieve the target LDL-c values. A useful tool for practice can be the 'risk traffic light' -⁠ an infographic clearly showing which risk category a patient falls into and what the recommended target LDL-c values are for each risk category. This makes it easier to plan tailor-made individual treatment.
Source: Chronic Heart Failure and Lipidology 11. 6. 2021

News Dosing of Enoxaparin in Morbidly Obese Patients

How to optimally dose enoxaparin in morbidly obese patients? This question was addressed by a randomized study, the results of which were published in the journal Annals of Pharmacotherapy.
Source: Thromboprophylaxis 11. 11. 2021

News Benefit of a single intra-articular injection of hyaluronic acid in the treatment of osteoarthritis

Viscosupplementation serves as a minimally invasive procedure to restore the rheological properties of synovial fluid and alleviate pain in patients with symptomatic osteoarthritis (OA). We now have a new 3rd generation hyaluronic acid (HA) product for intra-articular injections –⁠ Hyruan One, which uses HA cross-linking technology. The following text summarizes its benefits in the pharmacological management of OA.
Source: Osteoarthritis 6. 11. 2020

News Efficacy and Safety of Single-Application Hyaluronic Acid in Osteoarthritis Therapy

Causal therapy for osteoarthritis does not yet exist. Patients suffering from progressive joint disease are thus dependent on symptomatic medications that alleviate symptoms and partially slow the progression of osteoarthritis. An essential role in therapy is played by viscosupplementation in the form of intra-articular application of hyaluronic acid (HA). Currently, 3rd generation preparations intended for single application are preferred due to their efficiency and safety.
Source: Osteoarthritis 6. 11. 2020

News Pregabalin in the Hands of a General Practitioner

A recent Cochrane systematic review by authors from Oxford University examined the effect of pregabalin in the treatment of postherpetic neuralgia and diabetic neuropathy –⁠ conditions that general practitioners frequently encounter in their practice. Is pregabalin a suitable choice in these indications?
Source: Neuropathic Pain 18. 2. 2020

News Etiology and Therapy of Dry Eye Syndrome in a Nutshell

Dry eye syndrome, the most common diagnosis in outpatient ophthalmology practice, is a multifactorial disease with varying severity of symptoms. It reduces the quality of life and can also affect the patient's visual functions. Therapy is individualized according to the primary trigger of the disease and aims to restore the homeostasis of the ocular surface and tear film. Due to the rapid pace of modernization associated with numerous extrinsic factors contributing to the development of dry eye syndrome, its incidence is rising, as well as the number of topical therapeutic options.
Source: Ophthalmologic Diseases 15. 2. 2023

News What Next for Patients with CLL After Stopping Venetoclax?

Standard care for untreated patients with chronic lymphocytic leukemia (CLL) is therapy based on venetoclax. However, managing further treatment when venetoclax needs to be discontinued remains a relatively unexplored area without standardized protocols.
Source: Chronic Lymphocytic Leukemia 17. 7. 2020

News Combination of Targeted Therapy with Chemo in 1st Line in Patients with Left-Sided wtRAS mCRC

The preferred targeted therapy added to the combination with standard chemotherapy (CHT) for left-sided metastatic colorectal cancer (mCRC) with non-mutated RAS oncogene should be an antibody against the epidermal growth factor receptor (anti-EGFR), not against the vascular endothelial growth factor (anti-VEGF). This is based on a direct comparison of anti-EGFR panitumumab and anti-VEGF bevacizumab in the Japanese phase III PARADIGM study. The results were presented at the ASCO 2022 annual meeting.
Source: Colorectal Cancer 9. 6. 2023

News How to Dose Beta-Blockers After Myocardial Infarction?

In patients after myocardial infarction (MI), there is a frequent administration of too low doses of beta-blockers (BB) and rare upward titration of their dose after discharge from the hospital. The SWEDEHEART study investigated to what extent the BB dose actually affects 5-year cardiovascular (CV) outcomes, and data from the American registry allowed a focus on mortality after MI depending on BB dosing.
Source: Cardiovascular Continuum 23. 2. 2022

1 … 94 95 96 97 98 … 667
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#